Table 4 Association between (EORTC QLQ-C30, EORTC QLQ-BR23) functioning and symptom scales with GQoL of patients with breast cancer at TASH, Addis Ababa, Ethiopia
| Â | Variable | GQOL | COR (95% CI) | AOR (95% CI) | ||
|---|---|---|---|---|---|---|
Affected | Not affected | |||||
EORTC QLQ C-30 | Functional scales | |||||
 Physical functioning | Affected | 187 (68.0) | 46 (35.7) | 3.83 (2.47–5.96) |  | |
Not affected | 88 (32.0) | 83 (64.3) | 1.00 | Â | ||
 Role Functioning | Affected | 139 (50.5) | 18 (14.0) | 6.30 (3.63–10.94) |  | |
Not affected | 136 (49.5) | 111 (86.0) | 1.00 | Â | ||
 Emotional Functioning | Affected | 134 (48.7) | 30 (23.3) | 3.14 (1.96–5.03) |  | |
Not affected | 141 (51.3) | 99 (76.7) | 1.00 | Â | ||
 Cognitive Functioning | Affected | 121 (44.0) | 23 (17.8) | 3.62 (2.18–6.03) | 2.38 (1.32–4.31)* | |
Not affected | 154 (56.0) | 106 (82.2) | 1.00 | 1.00 | ||
 Social Functioning | Affected | 104 (37.8) | 27 (20.9) | 2.29 (1.41–3.75) |  | |
Not affected | 171 (62.2) | 102 (79.1) | 1.00 | Â | ||
Symptom scales | ||||||
 Fatigue | Affected | 204 (74.2) | 45 (34.9) | 5.36 (3.41–8.43) |  | |
Not affected | 71 (25.8) | 84 (65.1) | 1.00 | Â | ||
 Nausea and Vomiting | Affected | 87 (31.6) | 14 (10.9) | 3.80 (2.07–6.99) |  | |
Not affected | 188 (68.4) | 115 (89.1) | 1.00 | Â | ||
 Pain | Affected | 195 (70.9) | 26 (20.2) | 9.66 (5.84–15.96) | 7.99 (4.62–13.83)* | |
Not affected | 80 (29.1) | 103 (79.8) | 1.00 | 1.00 | ||
 Dyspnoea | Affected | 113 (41.1) | 18 (14.0) | 4.30 (2.47–7.48) |  | |
Not affected | 162 (58.9) | 111 (86.0) | 1.00 | Â | ||
 Insomnia | Affected | 152 (55.3) | 37 (28.7) | 3.07 (1.96–4.82) |  | |
Not affected | 123 (44.7) | 92 (71.3) | 1.00 | Â | ||
 Appetite loss | Affected | 166 (60.4) | 38 (29.5) | 3.65 (2.33–5.72) |  | |
Not affected | 109 (39.6) | 91 (70.5) | 1.00 | Â | ||
 Constipation | Affected | 122 (44.4) | 35 (27.1) | 2.14 (1.36–3.38) |  | |
Not affected | 153 (55.6) | 94 (72.9) | 1.00 | Â | ||
 Diarrhea | Affected | 27 (9.8) | 7 (5.4) | 1.89 (0.80–4.48) |  | |
Not affected | 248 (90.2) | 122 (94.6) | 1.00 | Â | ||
 Financial Difficulties | Affected | 187 (68.0) | 54 (41.9) | 2.95 (1.92–4.55) | 2.60 (1.56–4.35)* | |
Not affected | 88 (32.0) | 75 (58.1) | 1.00 | 1.00 | ||
EORTC QLQ BR-23 | Functional scales | |||||
 Sexual functioning | Affected | 70 (25.5) | 50 (38.8) | 0.54 (0.35–0.84) |  | |
Not affected | 205 (74.5) | 79 (61.2) | 1.00 | Â | ||
 Future Perspective | Affected | 181 (65.8) | 61 (47.3) | 2.15 (1.40–3.29) | 2.08 (1.24–3.49)* | |
Not affected | 94 (34.2) | 68 (52.7) | 1.00 | 1.00 | ||
Symptom scales | ||||||
 Systemic therapy side effects | Affected | 184 (66.9) | 44 (34.1) | 3.91 (2.51–6.08) |  | |
Not affected | 91 (33.1) | 85 (65.9) | 1.00 | Â | ||
 Breast Symptoms | Affected | 109 (39.6) | 24 (18.6) | 2.87 (1.73–4.76) |  | |
Not affected | 166 (60.4) | 105 (81.4) | 1.00 | Â | ||
 Arm symptoms | Affected | 119 (43.3) | 28 (21.7) | 2.75 (1.70–4.46) |  | |
Not affected | 156 (56.7) | 101 (78.3) | 1.00 | Â | ||